ACGIH: TWA 2.5 mg/m3NIOSH: IDLH 250 mg/m3; TWA 2.5 mg/m3
物理描述:
Ammonium fluoborate appears as odorless white crystals. Sinks and mixes with water. (USCG, 1999)
颜色/状态:
White powder, orthorhombic
气味:
Odorless
溶解度:
Water solubility (g/100 mL water): 3.09 at -1.0 °C; 5.26 at -1.5 °C; 10.85 at -2.7 °C; 12.20 at 0 °C; 25 at 16 °C; 25.83 at 25 °C; 44.09 at 50 °C; 67.50 at 75 °C; 98.93 at 100 °C; 113.7 at 108.5 °C
蒸汽压力:
0.001 lb/sq inch at 100 °F
自燃温度:
Not flammable (USCG, 1999)
分解:
When heated to decomposition it emits very toxic fumes of /hydrogen fluoride and nitrogen oxides and ammonia./
Maintain an open airway and assist ventilation if nescessary. treat coma, seizures, hypotension, and renal failure if they occur. There is no specific antidote. Administer activated charcoal (although boric acid is not well absorbed). Consider gastric lavage for large ingestions. /Boric acid, Borates, and Boron/
Hemodialysis is effective and is indicated after massive ingestions and for supportive care of renal failure. Peritoneal dialysishas not proved effective in enhancing elimination in infants. /Boric acid, Borates, and Boron/
In acute poisonings, if a large amount has been ingested and the patient is seen within one hour of exposure, gastrointestinal decontamination should be considered ... .It is important to keep in mind that vomiting and diarrhea are common, and severe poisoning may be associated with seizures. Therefore induction of emesis by syrup of ipecac is probably contraindicated in these exposures. Catharsis is not indicated if diarrhea is present. /Boric acid and Borates/
If ingestion of borate has been massive (several grams), or has extended over several days, administer intravenous glucose and electrolyte solutions to sustain urinary excretion of borate. Monitor fluid balance and serum electrolytes (including bicarbonate capacity ) regularly. Monitor cardiac status by ECG. Test the urine for proteins and cells to detect renal injury, and monitor serum concentration of borate. Metabolic acidosis may be treated with sodium bicarbonate. If shock develops, it may be necessary to infuse plasma or whole blood. Administer oxygen continuously. If oliguria (less than 25 to 30 mL urine per hour) occurs, intravenous fluids must be slowed or stopped to avoid overloading the circulation. Such patients should be referred to a center capable of providing intensive care for critically ill patients. /Boric acid and Borates/
Following daily oral intake of 6.4 mg sodium tetrafluoroborate by a volunteer for a period of 14 days, a daily average of 100% was excreted in the urine and 1.6% in the feces. The fluoride content of the volunteer's food was not determined. Sodium fluoroborate is therefore well absorbed, but the fluoride which enters the body is not stored. The authors attributed this to slow hydrolysis of the tetrafluoroborate ion. In another study with 3 volunteers and a study duration of 7 to 38 weeks, there were indications that fluoride which was absorbed in the form of sodium tetrafluoroborate was stored in the body. The amount was <10% of that absorbed into the bloodstream. /Sodium tetrafluoroborate/
In a further study... on the distribution of potassium tetrafluoroborate in various tissues, male albino rats (weighing 110 to 150 g; aged 11-13 weeks) were each iv injected with 1 umol 18F-labelled potassium tetrafluoroborate... . At 120 min after injection, the following relative specific activities (activity per gram of tissue/activity in serum) were determined: liver 0.29, spleen 0.37, kidney 0.60, lung 0.60, muscle 0.14, brain 0.03, femoral diaphysis 0.26, femoral epiphysis 0.29, incisors 0.27, cranial bone 0.27, cartilage 0.30. Further relative specific activities at 30, 120, and 240 min after injection were reported for serum/total injected dose as 1.75, 0.28, and 0.07, respectively, for muscle/serum as 0.14, 0.15, and 0.35, respectively, as well as for femoral epiphysis/serum as 0.35, 0.85, and 1.35, respectively, and for femoral epiphysis/femoral diaphysis as 1.0, 2.3, and 2.4, respectively. /Potassium tetrafluoroborate/
Rats (approx 200 g; 4 animals/group) were given a single ip injection of 5 ug 18F-labelled potassium tetrafluoroborate (it was not specified whether per kg bw or per rat). After 40, 60, 100, and 120 minutes, various organs were assessed for relative specific tetrafluoroborate activity (tissue/blood specific activity ratio). ...The highest activity was found in the thyroid gland, where it was 26 to 42 fold higher than in the other organs after 2 hours. Increases in dose to 50, 500, and 1000 ug potassium tetrafluoroborate did not increase the specific activity in the thyroid gland, but reduced it relative to the values found after administration of 5 ug, e.g. by about a factor of 20, 210 minutes after 1000 ug. /Potassium tetrafluoroborate/
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.
Multimetallic arrays: Symmetrical bi-, tri- and tetrametallic complexes based on the group 10 metals and the functionalisation of gold nanoparticles with nickel-phosphine surface units
作者:Edward R. Knight、Nina H. Leung、Yvonne H. Lin、Andrew R. Cowley、David J. Watkin、Amber L. Thompson、Graeme Hogarth、James D. E. T. Wilton-Ely
DOI:10.1039/b821947h
日期:——
occurs to yield a mixture of the complexes [M(S2CNC4H8NH2)L2]2+ and [(L2M)2(S2CNC4H8NCS2)]2+. However, the monometallic complexes [L2Ni(S2CNC4H8NH2)]2+ (L2=dppe, dppf) and [(L2Ni)2(S2CNC4H8NCS2)]2+ can be prepared without ready symmetrisation. Starting from the previously reported [(dppm)Ru(S2CNC4H8NH2)]2+, the heterotrimetallic products [(dppm)Ru(S2CNC4H8NCS2)M(dppf)]2+ (M=Pd, Pt) can be prepared without
Highly active, recoverable and recyclable transition metal-based metathesis catalysts and their organometallic complexes including dendrimeric complexes are disclosed, including a Ru complex bearing a 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene and styrenyl ether ligand. The heterocyclic ligand significantly enhances the catalytic activity, and the styrenyl ether allows for the easy recovery of the Ru complex. Derivatized catalysts capable of being immobilized on substrate surfaces are also disclosed. The present catalysts can be used to catalyze ring-closing metathesis (RCM), ring-opening (ROM) and cross metatheses (CM) reactions, and promote the efficient formation of various trisubstituted olefins at ambient temperature in high yield.
Large‐Scale Synthesis of a Niche Olefin Metathesis Catalyst Bearing an Unsymmetrical N‐Heterocyclic Carbene (NHC) Ligand and its Application in a Green Pharmaceutical Context
large‐scale synthesis of known Ru olefinmetathesis catalyst VII featuring an unsymmetrical N‐heterocyclic carbene (NHC) ligand with one 2,5‐diisopropylphenyl (DIPP) and one thiophenylmethylene N‐substituent is reported. The optimised procedure does not require column chromatography in any step and allows for preparation of up to 0.5 kg batches of the catalyst from simple precursors. The application profile
Synthesis and characterization of ruthenium(II) complexes based on diphenyl-2-pyridylphosphine and their applications in transfer hydrogenation of ketones
afford cationiccomplexes of formulation [RuH(CO)(κ1-P-PPh2Py)2(N-N)]+ (3–8) [N-N = en, 3; dimen, 4; diap, 5; bipy, 6; phen, 7; and dpa, 8], which have been isolated as their tetrafluoroborate salts. The complexes under investigation have been characterized by elemental analyses, spectroscopic and electrochemical studies. Molecular structures of 2, 3, 6, and 8 have been determined by single crystal X-ray